-
STATIN INITIATION TIME AFTER GRAVES' DISEASE DIAGNOSIS AND THE RISK OF GRAVES' ORBITOPATHY: A ONE-YEAR LANDMARK ANALYSIS
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING (CGM) FOR ADULTS WITH TYPE 1 DIABETES IN IRELAND
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Mar 18, 2026, 21:38 PM -
BREAST CANCER PATTERNS AND TREATMENT ACCESS IN DENMARK: IDENTIFYING OPPORTUNITIES FOR DECENTRALIZED CARE IN BREAST CANCER CARE (HEATMAP-ONKO-BREAST)
Mar 18, 2026, 21:38 PM -
REAL-WORLD DIAGNOSTIC DELAY, TREATMENT ACCESS, AND HEALTH SYSTEM BURDEN IN PRIMARY IMMUNODEFICIENCY/INBORN ERRORS OF IMMUNITY: EVIDENCE FROM THE UNITED STATES AND EX-US SETTINGS
Mar 18, 2026, 21:38 PM -
WHEN IS REAL-WORLD EVIDENCE SCIENTIFICALLY SOUND? EXPERT CONSENSUS ON SASS FOR CFL COMMUNICATION
Mar 18, 2026, 21:38 PM -
BURNOUT AMONG EMERGENCY CARE STAFF IN HUNGARY: PREVALENCE AND INTERVENTION POSSIBILITIES - A QUASI-EXPERIMENTAL STUDY
Mar 18, 2026, 21:38 PM -
FROM EVIDENCE TO PRICE: EMBEDDING PRICING STRATEGY IN EARLY MARKET ACCESS PLANNING
Mar 18, 2026, 21:38 PM -
PREFERENCES AND TRADE-OFFS FOR MASLD/MASH TESTING AMONG PATIENTS WITH TYPE 2 DIABETES: A DISCRETE CHOICE EXPERIMENT
Mar 18, 2026, 21:38 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Mar 18, 2026, 21:38 PM -
AN AUTOMATED FEASIBILITY ASSESSMENT TOOL FOR INDIRECT TREATMENT COMPARISONS ACROSS MULTIPLE ANALYTICAL METHODS
Mar 18, 2026, 21:38 PM -
COST OF ILLNESS AMONG ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) MEDICARE PATIENTS IN THE UNITED STATES BETWEEN 2011-2021
Mar 18, 2026, 21:38 PM -
OBSERVED CARDIOVASCULAR DISEASE PREVALENCE AMONG OBESE AND TYPE 2 DIABETES PATIENTS WITH AND WITHOUT GLP-1 TREATMENT
Mar 18, 2026, 21:38 PM -
AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Mar 18, 2026, 21:38 PM -
REAL-WORLD OUTCOMES OF SECOND-LINE THERAPIES IN RELAPSED/REFRACTORY DLBCL PATIENTS IN GERMANY: IMPACT OF FRONT-LINE TREATMENT-FREE PERIOD (2020-2022)
Mar 18, 2026, 21:38 PM -
TREATMENT DELAYS IN IBD: A MULTI-SITE REAL-WORLD ANALYSIS ACROSS UC HEALTH
Mar 18, 2026, 21:38 PM -
VALIDATION OF A TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) UNITED STATES (US) CLAIMS-BASED CODING ALGORITHM
Mar 18, 2026, 21:38 PM -
VALUE-BASED DECISION BOUNDARIES ANALYSIS (VB-DBA): A NOVEL METHOD OF INTEGRATING NETWORK META-ANALYSIS AND COST-EFFECTIVENESS MODELLING TO ESTIMATE PRICING THRESHOLDS BASED ON TARGET PRODUCT PROFILES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF THRUST CHUNA MANUAL THERAPY COMPARED WITH NON-THRUST CHUNA OR USUAL CARE IN PATIENTS WITH NON-ACUTE LOW BACK PAIN
Mar 18, 2026, 21:38 PM -
ANALYSIS OF HOSPITAL LENGTH OF STAY IN HONG KONG: EFFECTS OF AGE, CONDITIONS, AND COMORBIDITY INTERACTIONS
Mar 18, 2026, 21:38 PM
